Ignite Creation Date:
2024-05-05 @ 9:20 PM
Last Modification Date:
2024-10-26 @ 10:02 AM
Study NCT ID:
NCT00863681
Status:
COMPLETED
Last Update Posted:
2023-11-07
First Post:
2009-03-13
Brief Title:
BAY63-2521Long-term Extension Study in Patients With Pulmonary Arterial Hypertension
Sponsor:
Bayer
Organization:
Bayer
Study Overview
Official Title:
Long-term Extension Multicentre Multi-national Study to Evaluate the Safety and Tolerability of Oral BAY63-2521 1mg15 mg 20 mg 25 mg Tid in Patients With Symptomatic Pulmonary Arterial Hypertension PAH
Status:
COMPLETED
Status Verified Date:
2023-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
PATENT-2
Brief Summary:
Patients who have completed the 12 weeks treatment of the PATENT-1 trial study number 12934 will be asked to participate in this long term extension study with BAY63-2521
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2008-003610-94 | EUDRACT_NUMBER | None | None |